Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Screen Time Usage is High and Only Increasing. What Can We Do to Preserve Eye Health?

We spent a lot time on screens, whether for work or play, before the pandemic. Those in their early 20s spent an average of 25.9 hours per week just on their phones in 2018, according to Time. That number only rose in the span of two years, up to 28.5 hours in 2020. While there…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from CooperVision on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

We spent a lot time on screens, whether for work or play, before the pandemic. Those in their early 20s spent an average of 25.9 hours per week just on their phones in 2018, according to Time. That number only rose in the span of two years, up to 28.5 hours in 2020. While there are a myriad of eye conditions that can cause vision impairment, simply spending too much time on a screen can cause something called computer vision syndrome.

How does prolonged screen use contribute to eye conditions? And why does blue light from screens contribute to CVS? Well, when your eyes follow the same repetitive path, your eyes may experience overuse and straining, and a lack of blinking when staring at a screen can cause them to dry out. Blue light from screens can also result in retinal damage, increase risk of macular degeneration, and disrupt your sleep schedule.

What are basic guidelines for taking care of your eye health, whether you are a recreational screen user or use the screen for work? Justin Kwan, Senior Manager of Myopia Management, Coopervision, shares some strategies for preventing onset of vision impairments caused by excessive screen usage.

Justin’s Thoughts

“Our world is increasingly digital. I always joke that accountants are on three computer monitors, radiologists on six computer monitors. Whether you have a curve display, likely it’s straight ahead or too high. We need to get these multiple monitors down a little bit. We know that, you know, stuck in our basements, our home offices, and even at the workplace, lighting is not always enough and we need to get outside, even on breaks, as short as they may be.

Light is powerful, impacts our physiology in terms of our circadian rhythms and how we stay healthy. So, from an optometrist’s point of view, we need to be able to help our own cells with what life demands of us. We know that there are contact lenses like Biofinity and soon come MyDay Energist that have digital zone optics.

We’re gonna relieve some of that focusing that we click on ourselves and that work demands of us. There are glasses that shouldn’t just be focused for far and up close, but should be focused for the computer and down closer to us as well. You know, our smartphones tell us, you know, an iPhone every Sunday, what’s our average daily amount of screen time?

Doesn’t even, take into account our computer screen time as well. And smartphones are held really close, you know, less than 30 centimeters. For an adult’s kind of arm’s length is even closer than, than what our eyes have been, uh, used to. Looking back even decades ago. We’re not used to having things this close to us.

And so, when we think about the next generation coming up, our children, grandchildren, they need to get outside more too, because myopia develops and starts at a much younger age than before. And our education system is really focused around using digital devices for learning. So, with that, we need to kind of take an all-hands-on deck approach and help our own selves to kind of live a more, a visually healthy life.

Despite, I kind of mandated these 10 hours a day on computer screens. And to be able to take breaks, blink more to get our oil glands and tears healthy and use devices like contact lenses and glasses to really keep ourselves fresh and powering through when the demand is so great. So, with that, I hope you benefited from a couple of nuggets.”

CooperVision

Part of this channel

CooperVision

News, updates, and expert insights from CooperVision.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512